Agomab: Piper Sandler Sees 368% Upside on Ontunisertib for Fibrostenotic Crohn’s
Agomab trades at a deep discount to Sarepta and Abivax. Piper Sandler starts at Overweight with $60 PT.
NOTRELOAD AI
Apnimed Stock Jumps After BofA and Cantor Kick Off Coverage with Big Upside Targets
BofA and Cantor Fitzgerald initiate coverage on Apnimed with Buy and Overweight ratings for Oxnimbi, its oral therapy for obstructive sleep apnea.
Jazz Pharma Stock Hits All-Time High After FDA Approves Ziihera for Stomach Cancer
The FDA has approved Jazz's Ziihera as a first-line treatment for advanced HER2-positive gastroesophageal adenocarcinoma, establishing a new standard of care.
Cisco and Supermicro Partner to Deliver Rack-Scale AI Infrastructure with NVIDIA
Cisco and Supermicro are joining forces to make powerful, secure AI systems easier for companies to deploy and manage.
Summit’s Ivonescimab Delivers First Major PFS Win in EGFR-Mutated Lung Cancer After TKI Failure
HARMONi Phase 3 results in The Lancet Oncology show ivonescimab + chemo cuts progression risk nearly in half for post-TKI EGFR-mutated NSCLC.
Navitas Buys Claros for $233M to Complete Grid-to-xPU Power Chain for AI
Navitas plans to acquire Claros to complete its grid-to-xPU power chain with VPD & IVR tech for AI data centers, doubling its 2030 market to over $8B.